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Improved diagnostics and drug susceptibility testing for Mycobacterium tuberculosis are urgently needed. We developed a more
powerful mycobacteriophage (2GFP10) with a fluorescent reporter. Fluorescence-activated cell sorting (FACS) allows for rapid
enumeration of metabolically active bacilli after phage infection. We compared the reporter phage assay to GeneXpert MTB/RIF
for detection of M. tuberculosis and rifampin (RIF) resistance in sputum. Patients suspected to have tuberculosis were prospec-
tively enrolled in Durban, South Africa. Sputum was incubated with 2GFP10, in the presence and absence of RIF, and bacilli
were enumerated using FACS. Sensitivity and specificity were compared to those of GeneXpert MTB/RIF with an M. tuberculosis
culture as the reference standard. A total of 158 patients were prospectively enrolled. Overall sensitivity for M. tuberculosis was
95.90% (95% confidence interval (CI), 90.69% to 98.64%), and specificity was 83.33% (95% CI, 67.18% to 93.59%). In acid-fast
bacillus (AFB)-negative sputum, sensitivity was 88.89% (95% CI, 73.92% to 96.82%), and specificity was 83.33% (95% CI,
67.18% to 93.59%). Sensitivity for RIF-resistant M. tuberculosis in AFB-negative sputum was 90.00% (95% CI, 55.46% to
98.34%), and specificity was 91.94% (95% CI, 82.16% to 97.30%). Compared to GeneXpert, the reporter phage was more sensi-
tive in AFB smear-negative sputum, but specificity was lower. The 2GFP10 reporter phage showed high sensitivity for detection
of M. tuberculosis and RIF resistance, including in AFB-negative sputum, and has the potential to improve phenotypic testing
for complex drug resistance, paucibacillary sputum, response to treatment, and detection of mixed infection in clinical
specimens.
Mycobacterium tuberculosis remains a leading cause of deathworldwide (1–3). While the overall global tuberculosis (TB)
incidence has declined over the past decade, there are increasing
numbers of drug-resistant TB cases, and TB incidence in the
countries of southern Africa where HIV is endemic has reached
levels not seen in the United States or Western Europe since the
turn of the last century (3–6).
Drug-resistant TB remains a challenge to TB control due to
increased mortality, poor treatment outcomes, and a lack of rapid
comprehensive drug susceptibility testing (DST) (7–9). Where the
epidemics of drug-resistant TB and TB-HIV have converged,
most notably in southern Africa, the major diagnostic chal-
lenge is to perform comprehensive DST in paucibacillary spec-
imens (10–12).
GeneXpert MTB/RIF (GeneXpert) is an automated real-
time PCR system for the detection of M. tuberculosis and rifam-
pin (RIF) resistance. The strengths of GeneXpert include rapidity,
ease of use and interpretation, biohazard containment, and diag-
nostic accuracy in acid-fast bacillus (AFB) smear-positive sputum
(13, 14). However, GeneXpert has significant limitations, includ-
ing the inability to detect second-line or complex TB drug resis-
tance, distinguish between viable and nonviable M. tuberculosis,
and detect and distinguish minority M. tuberculosis subpopula-
tions (mixed or heteroresistant) (15–17). Importantly, GeneXpert
has decreased sensitivity in AFB smear-negative sputum, which is
common in TB-HIV (16).
Phenotypic diagnostics have the potential to perform DST for
drugs with complex or uncharacterized genetic mechanisms of
resistance, quantify level of resistance, distinguish viable from
nonviable M. tuberculosis, and detect mixed infection (18). Phe-
notypic assays are rapidly adapted to new drugs and have the po-
tential to measure treatment response. To date, however, with few
exceptions, phenotypic assays have been slow and/or cumber-
some to implement. Without rapid, comprehensive DST, patients
may start suboptimal regimens leading to amplification of TB
drug resistance (19–21).
Our group has extensive experience with the construction of
genetically modified mycobacterium-specific viruses (myco-
bacteriophages) for the genetic manipulation of M. tuberculosis
(18, 21, 22). We recently described the construction of a new,
more powerful reporter phage, 2GFP10, which uses a more effi-
cient promoter and a more powerful fluorescence reporter to al-
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low direct visualization of individual metabolically active bacilli
using fluorescence microscopy or fluorescence-activated cell sort-
ing (FACS), including in clinical sputum (23). The 2GFP10
phage allows for rapid detection of M. tuberculosis and phenotypic
DST in clinical sputum samples, including down to paucibacillary
concentrations (104 M. tuberculosis bacilli/ml). We performed
this study to assess the accuracy of the 2GFP10 phage to detect
M. tuberculosis bacilli and assess phenotypic drug resistance in the
sputum of TB suspects with and without HIV infection.
MATERIALS AND METHODS
Study population. Adult TB suspects were enrolled at an out-
patient municipal chest clinic (Prince Cyril Zulu Communica-
ble Disease Clinic) and a regional TB referral hospital (King
DinuZulu Hospital Complex) in Durban, South Africa from
November 2012 through May 2013. Study staff screened con-
secutive patients presenting with suspected TB based on eligi-
bility criteria. Adult patients were eligible to participate if they
were identified by clinic staff as pulmonary TB suspects, were
not currently taking TB medications, and had a documented
sputum AFB smear result and/or a Gene Xpert MTB/RIF result
in the clinic system. Initially, consecutive patients with a clinic
system result of AFB smear-positive or GeneXpert-positive
were preferentially enrolled to improve the efficiency of the
study (n  132). Subsequently, consecutive AFB smear-nega-
tive patients were enrolled (n  41). Study staff interviewed the
FIG 1 Schematic representation of study procedures. After sputum was collected at the clinic, it was brought to the experimental lab, decontaminated, and split
for testing by reporter phage (2GFP10) and conventional testing, including GeneXpert MTB/RIF. The gold standard was a combination of MGIT and agar
culture; all DST was done in solid media.
FIG 2 Schematic showing phenotypic drug susceptibility testing using reporter phage. Initially, mycobacteria are infected with reporter phage
(2GFP10). In the absence of antibiotics, the virus transcribes a fluorescent reporter gene (mVenus), and green fluorescent protein (GFP) is produced. In
the presence of an antibiotic to which M. tuberculosis is susceptible, transcription and translation is inhibited and fluorescence is markedly inhibited. In
drug-resistant M. tuberculosis, inoculation with an antibiotic to which the organism is resistant does not cause attenuation of the fluorescent signal.
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patients using a standardized questionnaire. Demographic,
symptom, and clinical data were recorded, including prior TB
history. HIV counseling and testing was offered to all patients
as per routine clinical practice. CD4 T-cell counts were ob-
tained, and antiretroviral therapy was offered at the discretion
of the treating physician.
All data were collected prospectively. Approval for the study
was obtained from ethics review boards at the University of Kwa-
Zulu-Natal, Albert Einstein College of Medicine, and the Kwa-
Zulu-Natal Department of Health and the eThekwini Municipal-
ity. Written informed consent was obtained from all participants.
Laboratory methods. After enrollment, a single sputum sam-
ple was obtained from each participant. The quality of the sputum
was assessed by the study staff, descriptively and in terms of vol-
ume. Sputum was transported using universal precautions to the
KwaZulu-Natal Research Institute for TB/HIV biosafety level 3
(BSL3) laboratory within 6 h after collection. The sputum was
decontaminated and liquefied using standard N-acetyl-L-cys-
teine-sodium hydroxide methods, centrifuged, and resuspended
in buffered solution. Ziehl-Neelsen (ZN) staining was performed.
AFB bacillary burden was graded as negative, scanty, 1, 2, or
3 according to standard definitions. Subsequently, the sample
was divided for parallel testing with standard TB culture tech-
niques, GeneXpert MTB/RIF (Cepheid, Sunnyvale, CA, USA),
and the 2GFP10 phage assay. Technicians certified by the Health
Professions Council of South Africa performed all laboratory test-
ing (Fig. 1).
Standard TB culture techniques included Middlebrook 7H10
agar plates and Bactec mycobacterial growth indicator tube
(MGIT) 960 broth (Becton Dickinson, Sparks, MD, USA).
Middlebrook agar plates were read at 3 weeks and 6 weeks for M.
tuberculosis growth. MGIT tubes were monitored for 42 days for
M. tuberculosis growth. MGIT cultures that were contaminated
were decontaminated and recultured. All positive cultures by
MGIT were identified as M. tuberculosis isolates by examining for
characteristic cording and repeat positive ZN staining. Additional
evidence that the samples were not nontuberculous mycobacteria
(NTM) species included a GeneXpert result identifying M. tuber-
culosis and by drug susceptibility pattern.
GeneXpert MTB/RIF was performed on sputum according to
the manufacturer’s protocol. Briefly, the sample reagent was
mixed at a three to one ratio with sputum and homogenized. If the
sample volume was 1 ml, sterile phosphate buffer (Merck, USA)
was added to bring the final volume to 1 ml. Two milliliters of
homogenized mixture was transferred into an GeneXpert MTB/
RIF assay cartridge. Results were obtained after the end of the run,
and qualitative and quantitative outputs were recorded. Microbi-
ology lab staff was blinded to clinical information and the initial
AFB status.
2GFP10 phage assay. The 2GFP10 phage expressing the
mVenus fluorescent protein from the PL promoter of the L5
mycobacteriophage was used for M. tuberculosis detection and
DST on patient samples (23). A high level of fluorescence in the
sputum  phage well indicates the presence of metabolically ac-
tive M. tuberculosis isolates; the persistence of fluorescence in the
presence of antibiotic indicates M. tuberculosis isolates which are
resistant to the antibiotic of interest (Fig. 2).
The aliquot of the decontaminated sputum sample for the
2GFP10 phage assay, collected during the week (Wednesday to
Friday), was resuspended in 7H9 medium and incubated at 37°C
prior to assay. On the following Monday, each specimen was in-
cubated with rifampin and loaded alongside two no-drug controls
on a 96-well plate. After overnight incubation the 2GFP10 phage
was added to the rifampin-treated well and one of the no-drug
controls. The additional no-drug well and a phage-only well were
used as negative controls. Laboratory grown M. tuberculosis cul-
ture was used as a positive-control in each plate. The plate was
read on a BD Accuri C6 Flow Cytometer (Becton, Dickinson and
Company, Franklin Lakes, NJ, USA) after 24 h using automated
settings. Fluorescence was measured by enumerating fluorescent
TABLE 1 Demographic and clinical characteristics of enrolled
participants












CD4 T-cell countb (no. of cells/mm3)
Known 38 (48.1)
Unknown 41 (51.9)




















Weight loss 110 (83.3)
Anyd 131 (98.5)
a Data shown are number (%) unless otherwise specified.
b Among HIV-infected patients.
c Three patients were MTB positive on solid medium culture only, due to
contamination of liquid culture.
d Cough, sweats, and/or weight loss.
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events by flow cytometry gating and cutoffs for positive results
were defined numerically.
Fluorescence-activated cell sorting (FACS) gating. FACS
gates and FACS thresholds were constructed based on preliminary
experiments in TB culture and spiked sputum using mycobacte-
ria, which constitutively expressed green fluorescent protein (24).
Briefly, the FACS gate was used to count the number of gated
fluorescent events in each experiment, which fell into the size and
fluorescent intensity characteristic of mycobacteria. M. tuberculo-
sis bacilli were detected based on increased numbers of fluorescent
events that fell within a FACS gate constructed using side scatter
(SSC) and fluorescent intensity in the FL-1 channel. Optimal ex-
perimental conditions were determined by various incubation
times, detergents, and drug concentrations while analyzing FACS
results. Relatively high FACS SSC thresholding was needed in spu-
tum to improve the fluorescent signal to noise ratio. A standard-
ized, invariant FACS gating strategy was used for all samples to
acquire and analyze results throughout the study.
Outcomes. The primary outcome was comparison of the
2GFP10 reporter phage result to that of a composite of liquid
culture and solid agar culture performed in the experimental lab-
oratory on the same sputum sample. If either MGIT or agar was
positive for detection of M. tuberculosis isolates, the reference
standard was considered positive. To determine rifampin resis-
tance, drug susceptibility testing was done on 7H10 according to
standard protocols and techniques. A secondary outcome was
comparison to GeneXpert MTB/RIF performed on the same spu-
tum sample. Outcomes were stratified by sputum bacillary load
grade (smear status) and by HIV status.
Statistical methods. Receiver operating characteristic (ROC)
curves were calculated by plotting the sensitivity against 1-speci-
ficity for all values of gated fluorescent events (representing fluo-
rescent M. tuberculosis). Separate cut points were determined for
detection of M. tuberculosis and detection of RIF resistance. For
detection of M. tuberculosis, cut points were chosen to optimize
sensitivity while preserving specificity. For detection of RIF
resistance, cut points were chosen to optimize specificity while
preserving sensitivity. Sensitivity, specificity, and 95% confi-
dence intervals (CI) were calculated using standard methods.
ROC curves were calculated using SPSS (Version 21.0; IBM
Corp., Armonk, NY).
Infection control methods. Running a sample through the
flow cytometer may create an aerosol. Therefore, the flow cytom-
eter was kept under a biosafety hood in a BSL3 facility. Preliminary
experiments with nonpathogenic mycobacteria revealed no con-
tamination outside the biosafety hood using this approach. All
FIG 3 Flow cytometry (FACS) analysis of 3 representative clinical sputum samples. Flow cytometry plots showing side scatter (SSC) (y axis) plotted
against green fluorescence protein (Log GFP) (x axis). Columns represent sputum from 3 patients. Column 1 is sputum from a patient who did not have
TB (true negative). Column 2 is sputum from a patient with drug-susceptible TB (drug-susceptible TB). Column 3 is sputum from a patient with
multidrug-resistant TB (MDR-TB). Row A, sputum alone; Row B, sputum  reporter phage; Row C, sputum  reporter phage  RIF. FACS gate is the
red dashed line. For the true negative, there is no increase in gated events after inoculation with reporter phage (1B) because there is no viable M.
tuberculosis in sputum. For the drug-susceptible TB patient, fluorescent events increase after the addition of reporter phage (2B) but decrease with RIF (2C)
indicating RIF-susceptibility. For the MDR-TB patient, there is an increase in gated events after reporter phage (3B) and no substantial decrease after RIF (3C)
indicating RIF resistance.
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BSL3 procedures and protocols were observed. The flow cytome-
ter used in these experiments was exclusively used with mycobac-
teria. Periodic decontamination was performed as per manufac-
turer’s recommendations.
RESULTS
A total of 173 patients were prospectively enrolled (148 at the
municipal chest clinic and 25 at a TB referral hospital). Sputum
was collected from all 173 patients and transported to the lab
for analysis (median sputum volume, 2 ml; interquartile range
[IQR], 1 to 3 ml). Of these, 10 samples did not have the phage
assay performed (FACS analysis was not performed in a timely
fashion), and 5 did not have interpretable M. tuberculosis cul-
ture results. Phage assay was performed for 158 samples, which
were paired with a reference M. tuberculosis culture sample and
were included in the present study. Of these, 155 had an interpre-
table GeneXpert MTB/RIF result. Complete demographic and
clinical data were collected on 155/158 patients. The mean time to
results for the phage assay was 7.5 days (range, 5 to 9 days) versus
18.2 days for MGIT (IQR, 6.7 to 42 days) among patients who did
not have initial contamination.
Patients were more likely to be male (52.9%) than female
(47.1%), younger (median age, 33 years), and had a substantial
burden of HIV disease (63.7% of patients were HIV tested). Many
had not had previous HIV testing, and of those tested only a mi-
nority were on antiretroviral therapy (ART) (35.4%), probably
reflecting the fact that many patients were presenting at a primary
care setting (Table 1).
The reporter phage assay allowed us to accurately distinguish
between true-negative patients (who did not have TB), drug-sus-
ceptible TB patients, and multidrug-resistant TB (MDR-TB) pa-
tients (RIF resistant) (Fig. 3). We evaluated the accuracy of the
2GFP10 reporter phage assay by calculating ROC curves and
area under the curve (AUC) by means of c-statistic. A standard-
ized invariant FACS gate had excellent test characteristics in de-
tecting M. tuberculosis (c-statistic, 0.936) and RIF-resistant M. tu-
berculosis (c-statistic, 0.935). We looked at paucibacillary samples
in two ways, by AFB smear status and by time to TB culture pos-
itivity (TTP) in liquid growth medium (25). AFB smear-negative
and high-TTP samples test characteristics were excellent for de-
tection of M. tuberculosis and RIF resistance (see Fig. S1 and S2 in
the supplemental material).
In AFB smear-positive patients, the sensitivity of the 2GFP10
reporter phage was 95.90% (95% CI, 90.69% to 98.64%), and in
AFB smear-negative patients, it was 88.89% (95% CI, 73.92% to
96.82%). Specificity was not estimable in smear-positive patients
since all had TB by MGIT culture; specificity was 83.33% (95% CI,
67.18% to 93.59%) in AFB smear-negative patients. With respect
to detecting RIF-resistant M. tuberculosis, the sensitivity in smear-
positive sputum was 85.00% (95% CI, 62.08% to 96.62%), and the
specificity was 84.85% (95% CI, 73.89% to 92.47%). In smear-
negative sputum, the sensitivity for detecting RIF-resistant M. tu-
berculosis was 90.00% (95% CI, 55.46% to 98.34%), and the spec-
ificity was 91.94% (95% CI, 82.16% to 97.30%). When we
stratified by high TTP as a proxy for bacillary load, the reporter
phage test characteristics were similar to the reported values for
AFB smear-negative sputum. The majority of HIV-infected pa-
tients were AFB smear-negative (58.3%). In the HIV-coinfected
strata, sensitivity of the reporter phage was 84.21% (95% CI,
72.13% to 92.50%) to detect M. tuberculosis and 90.00% (95% CI,
68.26% to 98.47%) to detect rifampin resistance (Table 2).
DISCUSSION
This study demonstrates the excellent test characteristics of a next-
generation reporter mycobacteriophage, 2GFP10, in detection
of M. tuberculosis and rifampin resistance in clinical sputum. This
study was performed in a high-burden HIV setting with a substan-
tial burden of HIV-infected participants and AFB smear-negative
sputum. The reporter phage performed extremely well in HIV-
infected patients and in AFB smear-negative samples, highlighting
its potential role in this critical setting. Compared to GeneXpert
MTB/RIF, the reporter phage had improved sensitivity in AFB
smear-negative sputum; however, specificity was lower. The re-
porter phage also provided additional information compared to
that of GeneXpert and liquid TB culture. Using the reporter phage
in combination with GeneXpert would yield an additional 4 diag-
nosed cases of MDR-TB in this study. One case found to be RIF
resistant by Xpert and 2GFP10 was initially drug-susceptible on
conventional DST. When conventional DST was repeated, it was
found to in fact be MDR-TB.
Comparative advantages for the phage assay to liquid M. tuber-
culosis culture include superior time to results for TB detection.
TABLE 2 Sensitivity and specificity of reporter phage assay (2GFP10)
to detect Mycobacterium tuberculosis and rifampin resistance compared








All patients 122/158 119/155
Sensitivity 95.90 (90.69–98.64) 94.12 (88.25–97.59)
Specificity 83.33 (67.18–93.59) 97.22 (85.42–99.54)
AFB smear positive 92/94 91/92
Sensitivity 98.84 (93.67–99.81) 100.0 (95.94–100)
Specificity b b
AFB smear negative 30/64 28/63
Sensitivity 88.89 (73.92–96.82) 75.00 (55.12–89.26)
Specificity 83.33 (67.18–93.59) 97.14 (85.03–99.52)
HIV positive 53/79 53/79
Sensitivity 84.21 (72.13–92.50) 92.45 (81.77–97.86)
Specificity 81.82 (59.70–94.70) 95.65 (77.98- 99.27)
Detection of rifampin
resistance
All patients 26/158 24/155
Sensitivity 86.67 (69.26–96.16) 83.33 (62.60–90.97)
Specificity 88.28% (81.41–93.29) 95.16 (94.19–99.75)
AFB smear positive 19/94 19/92
Sensitivity 85.00 (62.08–96.62) 94.74% (73.90–99.12)
Specificity 84.85 (73.89–92.47) 98.63 (92.57–99.77)
AFB smear negative 7/64 5/63
Sensitivity 90.00 (55.46–98.34) 40.00 (6.49–84.60)
Specificity 91.94 (82.16–97.30) 98.28 (90.73–99.71)
HIV positive 17/79 17/79
Sensitivity 90.00 (68.26–98.47) 82.35 (56.55–95.99)
Specificity 88.14 (77.06–95.07) 100.0 (94.17–100)
a Combined reference standard, MGIT 960  agar culture and DST performed in
experimental lab on the same sputum sample as for the reporter phage assay. Data
shown are number of patients/total no. of patients or percent (95% CI).
b No specificity value since all AFB smear positives were combined reference MTB
positive.
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For drug susceptibility testing, the TB culture may require up to an
additional 42 days after M. tuberculosis detection to obtain solid
agar DST results (26). GeneXpert has excellent test characteristics
in AFB smear-positive sputum (16). However, in a systematic re-
view, the pooled sensitivity of GeneXpert in AFB smear-negative
sputum was 67% (27), current DST with GeneXpert is limited to
Rifampin, and in general genotypic DST is not accurate where the
genetic mechanism of drug resistance is uncharacterized, incom-
pletely characterized, complex, or in the presence of mixed infec-
tion. In addition, genotypic tests do not distinguish viable from
nonviable cells and, therefore, are suboptimal to measure treat-
ment response.
Limitations include those associated with the phage assay
and with the study design. The current reporter phage assay
includes reduced specificity and equipment requirements. De-
creased specificity may be due to viral host promiscuity and/or
choice of cut point. The reporter phage may infect nontuber-
culous mycobacteria (NTM) as well as M. tuberculosis. To ad-
dress this limitation, we have developed a control condition to
detect NTM (4-nitrobenzoic acid) going forward (28). To im-
prove the specificity, we might increase the FACS cut point (in-
crease the number of FACS gated events required to classify the
sample as positive) with a trade-off of decreased sensitivity. This
higher specificity would be useful in a “rule out” test, for example,
in determining second-line resistance in samples found to be ri-
fampin resistant by GeneXpert. In this study, we used a clinical
FACS (BD Accuri C6), which is inexpensive and in wide clinical
use. Ultra-inexpensive flow cytometers are being developed,
which may be amenable to the reporter phage assay (29). An im-
portant operational limitation to this assay is the requirement for
a BSL3 laboratory and biosafety cabinet since we are interrogating
the metabolic activity of live cells. Compared to GeneXpert, the
assay takes substantially longer for a result but is faster than M.
tuberculosis culture.
There are also limitations related to study design. We enriched
for TB drug resistance by enrolling at a TB referral center as well as
a municipal chest clinic. This strategy improved efficiency but
prevented estimation of positive and negative predictive value. A
single sputum sample was used for each diagnostic test, which
improved our ability to compare tests but may have reduced the
sensitivity of each individual test by reducing the quantity of spu-
tum tested.
In summary, the 2GFP10 reporter phage showed high sen-
sitivity for detecting M. tuberculosis and RIF resistance, including
in AFB smear-negative sputum, an important clinical subset in
HIV endemic populations. These results represent a significant
advance over earlier-generation reporter phages and are promis-
ing given the potential for the reporter phage to detect phenotypic
resistance to drugs other than RIF. The current lack of a rapid TB
diagnostic with comprehensive DST is a critical obstacle to im-
prove patient outcomes and reduce the transmission of drug-re-
sistant M. tuberculosis strains. Advanced phenotypic assays such as
2GFP10 may have an important role to play.
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